Rachel Werner on new research exploring how nursing homes with private equity investment compared to other nursing homes on cost, outcomes and staffing.
Long-Term Care
Posted inCost of Care
The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Posted inCost of Care
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Posted inMental Health
The Aducanumab Aftermath: The Patient
One patient shares her hopes and concerns about a costly new Alzheimer’s drug.
Posted inCost of Care
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Posted inCost of Care
The FDA’s Pressure-Packed Alzheimer’s Drug Decision
The FDA weighs whether to approve a controversial new Alzheimer’s drug.
Posted inInsurance
Biden’s $400 Billion Bet on Caring for Older and Disabled Americans at Home
President Biden wants to make a huge investment in an often neglected part of the health care system.
Posted inHealth Equity
Alzheimer’s Can Wreak Financial Havoc Years Before Diagnosis
Ezra Golberstein on new research that suggests negative financial consequences can start years before an Alzheimer’s diagnosis.
Posted inPublic Health
We Need You
Why are so many nursing home workers hesitant to get vaccinated, and what can be done to turn those numbers around?
Posted inPublic Health
Have Private Equity Nursing Homes Done Worse With COVID-19?
Tamara Konetzka on research exploring the impact of nursing home ownership on COVID-19 fatalities.